IBR Inc. is a Swiss contract research organisation with a core competence in inflammation research and over 10 years experience of providing preclinical and clinical R&D services to biotechnology and pharmaceutical companies. A multidisciplinary team of scientists, GLP-compliant laboratories and a broad portfolio of validated methods cover the drug development process from early lead optimization to clinical studies. Ensuring access to expert knowledge in all phases of the drug development process, IBR Inc. provides cutting edge bioanalytical services, while meeting the regulatory specifications and the time schedule of its customers. IBR Inc. provides method development for preclinical R&D covering drug characterization, mode of action, pharmacology, preclinical safety evaluation, immune-profiling and cell based assays. In clinical R&D, IBR Inc. provides method development, validation and performance of sample analysis.